Allogeneic transplantation using peripheral blood stem cells

Best Practice & Research. Clinical Haematology
N H Russell, J L Byrne

Abstract

Over the past 9 years there has been a remarkable increase in the use of peripheral blood stem cells (PBSC) for allogeneic transplantation, primarily for matched sibling transplants but also increasingly for unrelated donor transplantation. In 1999 over 50% of all sibling transplants and over 25% of unrelated donor transplants reported to the European Group for Blood and Marrow Transplantation (EBMT) used PBSC. The major reason for this increasing use of PBSC relates to the rapid haemopoietic recovery seen which mirrors the advantages of using PBSC in autologous transplantation. This improvement in engraftment is a consequence of the larger number of stem cells that can be collected from G-CSF-mobilized peripheral blood compared to bone marrow. Evidence from randomized trials now shows a survival advantage for the use of PBSC in patients with advanced leukaemia. The reason for this improved survival appears primarily to relate to a reduced risk of transplant-related mortality and, possibly, a reduced risk of relapse, However, these randomized studies have also confirmed that there is an increased risk of chronic graft-versus-host disease associated with PBSC transplantation and further follow-up is required to determine the lon...Continue Reading

References

Jun 1, 1996·British Journal of Haematology·N RusselN Schmitz
May 1, 1997·British Journal of Haematology·P AnderliniM Körbling
Jun 13, 2000·Bone Marrow Transplantation·D HeldalS A Evensen
Mar 10, 2001·Transfusion·U PlatzbeckerK Hölig
Mar 10, 2001·Transfusion·J de La RubiaM A Sanz

❮ Previous
Next ❯

Citations

Sep 21, 2010·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·C P LarsenL S Kean
Aug 19, 2014·Cytokine & Growth Factor Reviews·Linda J Bendall, Kenneth F Bradstock

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.